Aureka Biotechnologies (寻明生科)
UC Irvine spin-out designing functional antibodies with generative AI, backed by its own ultra-high-throughput wet lab.
1. Core Product / Service
Aureka (founded 2023) designs antibodies that do more than bind. Its pipeline covers multispecifics, agonist antibodies, internalizing antibodies, pH-switch antibodies and epitope-specific binders [1][2]. The design engine is AuraIDE, a functional-antibody design platform with an agent layer on top. A partially open-source version, OpenDDE, was released in July 2026 [5]. The Series B is earmarked for training larger biological foundation models and upgrading the company's lab-in-the-loop system [4][7].
Pipeline. Eight programs across cardiometabolic, immunology and CNS indications [2]. Disclosed codes include:
- AURA083: multispecific.
- AURA104 / AURA105: agonists.
- AURA136: internalizing.
- AURA053: pH-switch.
- AURA010 / 012 / 014: epitope-specific.
As of April 2026, one asset was "about to enter the clinic" and two were in IND development [2]. A stated target of two clinical-stage assets and four PCCs by year-end is a plan, not a result.
Wet-lab model: built in-house, and central to the strategy. Aureka runs its own high-throughput experimental platforms, which is rare among Chinese AI-native startups [1][2]:
- Microfluidic single-cell functional screening. The company says one run can characterize 1–10 million molecules, about five to six orders of magnitude more than 96-well plates.
- Automated intracellular directed evolution in yeast, used to generate affinity data.
Both feed a lab-in-the-loop cycle. The April 2026 release says it has R&D centers and high-throughput platforms in both the US and China [2]. Lab size, exact sites and equipment lists are not disclosed, and the throughput figures are the company's own.
2. Target Users & Pain Points
- Its own pipeline. Functional antibodies such as agonists and conditionally active binders are hard to find with standard binding screens, because the property that matters is cellular function, not affinity.
- Big-pharma partners. Aureka also earns platform revenue. It reports collaborations or NewCo structures with several US and European multinationals, and BD revenue at the "tens of millions of US dollars" level over two years [2]. One top-5 pharma collaboration reportedly produced three programs, including a GPCR target, in two months [2].
3. Competitive Landscape
| Player | Positioning | Vs. Aureka |
|---|---|---|
| absci | US generative-antibody company with in-house wet lab | Closest model analog. Absci is listed and has clinical assets; Aureka targets function-first designs |
| generate-biomedicines | US generative protein / antibody platform | Much larger capital base and clinical programs |
| nabla-bio | US de novo antibody design, including GPCRs | Overlaps on hard membrane targets. Nabla is platform-and-partnership-first |
| chai-discovery | US foundation-model lab for molecular design | More of a model company; Aureka's edge is proprietary functional data |
| anew-labs | ByteDance spin-out with multi-modality pipeline | Better funded, but has disclosed no wet-lab build |
| adaptyv-bio | Protein-testing service | The outsourced alternative to the screening Aureka does in-house |
4. Unique Observations
- It is the clearest "wet-heavy" Chinese AI-native startup. Most peers lean on CROs or academic labs. Aureka treats experimental throughput as its data moat, which is closer to the US AI-native playbook than to the typical Chinese pattern of a small core lab plus heavy CRO outsourcing.
- Its nationality is a boundary case. Press releases are datelined Laguna Hills/Shanghai, English sources place headquarters in Irvine, and the founder is a UC Irvine professor. Most capital is Chinese or Asian, and labs are in both countries. Whether it counts as a "Chinese startup" depends on the definition. The Chinese legal entity's name and address are not disclosed.
- It is a hybrid, not pure pipeline. Meaningful BD revenue from multinationals funds the platform. This is the most common model among the Chinese AI-native drug startups founded in 2023 or later.
5. Financials / Funding
| Round | Date | Amount | Investors |
|---|---|---|---|
| Seed | 2023 | not disclosed | NRL Capital (纽尔利资本), among others |
| Series A | Nov 2025 | "tens of millions of USD" | Co-led by 5Y Capital and Qiming; NRL followed; Agentic Ventures among other participants [1][8] |
| Series A+ | Apr 2026 | US$35M | Led by HongShan (HSG, formerly Sequoia China); Matrix China (MPCi) and Boyuan followed; 5Y, Qiming and NRL re-upped [2][6]. One English report also names BioTrack Capital [8] |
| Series B | Aug 2026 | US$100M, in tranches | First tranche solely from Granite Asia; a later tranche led by an unnamed strategic investor, with HighLight Capital (弘晖) participating; Qiming, Matrix China and NRL followed on [3][4] |
- Total raised: close to US$200M [3][4].
- Series B date: Chinese reports place the close around 10 August 2026 [3], and English coverage appeared on 11 August [8]. The Goodwin law-firm announcement is dated later in August [7].
- Valuation: not disclosed.
6. People & Relationships
- Co-founder & CEO: 赵伟安 (Weian Zhao), professor of biomedical engineering and pharmaceutical sciences at UC Irvine. Honors include MIT TR35 and the NIH Director's New Innovator Award [9]. Whether he still holds the full-time faculty post is not disclosed.
- Co-founder: Alon Wellner, Chief Innovation Officer [8].
- Origin: UC Irvine spin-out [8][9].
- Investors: Qiming, 5Y Capital, HongShan, Matrix China, Boyuan, Granite Asia, HighLight Capital, NRL Capital.
- Peers: absci, generate-biomedicines, nabla-bio, anew-labs, pinnacle-medicines.
Sources
- PEdaily (Series A) — https://news.pedaily.cn/202511/557131.shtml
- PEdaily (Series A+) — https://news.pedaily.cn/202604/563248.shtml
- Eastmoney (Series B) — https://finance.eastmoney.com/a/202608123839456130.html
- DealStreetAsia — https://www.dealstreetasia.com/stories/aureka-series-b-granite-asia-491777
- BAAI Hub — https://hub.baai.ac.cn/view/57052
- 36Kr EU — https://eu.36kr.com/en/p/3784480103455748
- Goodwin — https://www.goodwinlaw.com/en/news-and-events/news/2026/08/announcements-lifesciences-goodwin-advises-aureka-biotechnologies-intellectual-property-aspects
- AllSci — https://allsci.com/news/venture-financing/ai-drug-discovery-funding-aureka-closes-usd-100m/
- Zhao Lab, UC Irvine — https://faculty.sites.uci.edu/zhaolab/news-2